2,000
Participants
Start Date
October 31, 2010
Primary Completion Date
November 30, 2017
Study Completion Date
December 31, 2017
5-Fluorouracil
5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
Leucovorin
Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles
Oxaliplatin
Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
Capecitabine
Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
Oxaliplatin
Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
5-Fluorouracil
5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles
Leucovorin
Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles
Capecitabine
Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
Oxaliplatin
Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
Oxaliplatin
Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
University Hospital of Crete, Dep of Medical Oncology, Heraklion
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER